Understanding and intervening in HIV-associated tuberculosis.

Area of Science:

• Immunology
• Infectious Diseases
• Public Health

Background:

• Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) co-infection presents a spectrum from severe disseminated disease to asymptomatic infection.
• Distinct pathological features at either extreme necessitate specific diagnostic and therapeutic strategies.
• Current approaches require augmentation with novel therapeutics targeting both the pathogen and host immune responses.

Purpose of the Study:

• To review the diverse clinical presentations of HIV-associated tuberculosis.
• To discuss the pathological correlates and distinct management approaches for different disease spectrums.
• To highlight the need for novel therapeutics and immune modulation strategies in co-infected patients.

Main Methods:

• Literature review focusing on clinical presentations, pathology, and treatment of HIV-associated tuberculosis.
• Analysis of the role of antiretroviral therapy (ART) in co-infection, including immune reconstitution inflammatory syndrome (IRIS).
• Discussion of potential therapeutic targets and immune modulatory interventions.

Main Results:

• HIV-associated TB ranges from acute, life-threatening disseminated disease to occult, asymptomatic infection.
• Antiretroviral therapy enhances anti-TB treatment efficacy but can precipitate TB-IRIS in high-bacillary states.
• Immune modulation is key to controlling tissue destruction in immune reconstituting patients.

Conclusions:

• Management of HIV-associated TB requires tailored approaches based on clinical presentation and bacillary load.
• Novel therapeutics and host-directed immune modulation are essential for improving outcomes.
• Interventions must be adaptable for sustainable implementation in programmatic settings.